Horii, Rie http://orcid.org/0000-0002-4227-2739
Nitta, Hiroaki
Nojima, Masanori
Maruyama, Reo
Ueno, Takayuki
Ito, Yoshinori
Ohno, Shinji
Banks, Peter
Kanda, Hiroaki
Akiyama, Futoshi
Article History
Received: 24 September 2020
Revised: 1 January 2021
Accepted: 15 January 2021
First Online: 26 January 2021
Compliance with ethical standards
:
: This study was approved by the ethical committee of the Japanese Foundation for Cancer Research on August fourth, 2014 (No. 2014-1033). General consent for the use of specimens was obtained preoperatively from all patients participating in this study.
: This work has not been published before, and it is not under consideration for publication anywhere else. Its publication has been approved by all authors.
: RH reports receiving honoraria from Chugai Pharmaceutical Co., Ltd. and US-Lead Inc. HN is an employee of Roche Tissue Diagnostics. MN reports receiving honoraria from Chugai Pharmaceutical Co., Ltd. TU reports receiving honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd. and Novartis Pharma K.K. YI reports receiving research grants from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., PAREXEL International Corp., Novartis Pharma K.K., Eli Lilly Japan K.K., and MSD K.K. SO reports receiving honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K. and Eisai Co., Ltd. FA reports receiving a consulting fee from Sysmex Corporation and research grants from Roche Tissue Diagnostics and Hitachi, Ltd. No potential conflicts of interest were disclosed by the other authors.
: Not applicable